Qiagen to consolidate and expand in Maryland; Myriad Genetics leads Utah Dx labs in Medicare-related revenue;

> Qiagen ($QGEN), the Dutch diagnostics and lab testing giant, said it would combine three Maryland sites into two campuses in the state and invest $10 million more to accommodate future growth. Story

> Exact Sciences ($EXAS), developer of the Cologuard colon cancer test, ended up raising nearly $138 million in a secondary offering of 11.5 million shares, a larger-than-expected haul in which underwriters exercised their 1.5-million-share overallotment option. Story (reg. req.)

> Utah's Myriad Genetics ($MYGN) pulls in twice as much revenue from Medicare as all other diagnostics laboratories and related businesses in the state combined, according to an analysis of federal data. Story

> At a recent conference, California's ICB International unveiled a new tracer that helped image alpha-synuclein in the brains of Parkinson's-like mice. Release

> Saladax Biomedical is rolling out a blood test to help doctors better manage the use of a particular chemotherapy drug for various cancers. Release

> Invetech will back the development and production of Biocartis' platform for biomarker analysis, both companies announced on April 15. Story (reg. req.)

> A new blood-based biomarker could help predict breast cancer recurrence and a patient's treatment response. Story

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.